NASDAQ:AVNR - Avanir Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA).

Receive AVNR News and Ratings via Email

Sign-up to receive the latest news and ratings for AVNR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:AVNR
CUSIP05348P40
Phone+1-949-3896700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Avanir Pharmaceuticals (NASDAQ:AVNR) Frequently Asked Questions

What is Avanir Pharmaceuticals' stock symbol?

Avanir Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVNR."

Has Avanir Pharmaceuticals been receiving favorable news coverage?

News articles about AVNR stock have been trending negative on Sunday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Avanir Pharmaceuticals earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned media headlines about the healthcare company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

What other stocks do shareholders of Avanir Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanir Pharmaceuticals investors own include Tellurian (TELL), Netflix (NFLX), Avid Bioservices (CDMO), Nokia Oyj (Nok), GT Advanced Technologies (GTATQ), Ariad Pharmaceuticals (ARIA), Groupon (Grpn), Intel (INTC), CytRx (CYTR) and Arena Pharmaceuticals (ARNA).

How do I buy shares of Avanir Pharmaceuticals?

Shares of AVNR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Avanir Pharmaceuticals' official website?

The official website for Avanir Pharmaceuticals is http://www.avanir.com/.

How can I contact Avanir Pharmaceuticals?

Avanir Pharmaceuticals' mailing address is 20 Enterprise Ste 200, ALISO VIEJO, CA 92656-7104, United States. The healthcare company can be reached via phone at +1-949-3896700.


MarketBeat Community Rating for Avanir Pharmaceuticals (NASDAQ AVNR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  119 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about Avanir Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVNR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVNR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by MarketBeat.com Staff

Featured Article: Compound Interest

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel